plus 3, AmpliVox Donates Pink Podiums for Breast Cancer Awareness ... - PR Inside |
- AmpliVox Donates Pink Podiums for Breast Cancer Awareness ... - PR Inside
- Acupuncture May Cut Hot Flashes, Boost Sex Drive in Breast Cancer ... - US News and World Report
- Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer - MSN Money
- EARLY Act Included in Senate Health Reform Legislation - PR-USA.net
| AmpliVox Donates Pink Podiums for Breast Cancer Awareness ... - PR Inside Posted: 29 Dec 2009 01:58 PM PST 2009-12-29 22:53:35 - NORTHBROOK, IL -- (Marketwire) -- 12/29/09 -- AmpliVox announced an unprecedented corporate campaign to support the cause for Breast Cancer Awareness. To raise the bar on "being heard," AmpliVox donates one pink podium to every breast cancer awareness related presentation or event, on a free loan-per-event basis. The Pink Podium Promise program will help to connect with new audiences and heighten the awareness and education on the importance of the early detection of breast cancer. Our Breast Cancer Awareness Page: :  www.ampli.com/opo/PinkPodiumPromisePR.htm : for images and information.
"We've affirmed our ongoing commitment to the fight against breast cancer, which AmpliVox supports through its Pink Podium Promise. Donating the Pink Podium to breast cancer awareness related presentations and events is our way of allowing all voices to be heard," commented Don Roth, CEO of AmpliVox.
The Pink Podium is the Pinnacle Multimedia Hard Shell Plastic Podium, a virtually indestructible hard plastic lectern that can survive tough abuse indoors or outdoors. To request a Pink Podium, please email or call the contact below.
About AmpliVox
Contact:
Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Acupuncture May Cut Hot Flashes, Boost Sex Drive in Breast Cancer ... - US News and World Report Posted: 30 Dec 2009 11:12 AM PST By Amanda Gardner WEDNESDAY, Dec. 30 (HealthDay News) -- Acupuncture is just as good as standard medication to ease hot flashes and other uncomfortable symptoms in women undergoing breast cancer treatment. And as an added bonus, the needle treatment may boost the patient's sex drive and contribute to clearer thinking. "I think the data shows you that acupuncture is a good option for these patients [and] it has no side effects," added Dr. Eleanor Walker, division director of breast services in the department of radiation oncology at Henry Ford Hospital in Detroit, and lead author of a study appearing online Dec. 28 in the Journal of Clinical Oncology. But another expert warned against taking the findings too seriously at this stage. "It's provocative but the problem is it's a small number of patients and, having participated in research trials in vasomotor [hot flashes, night sweats, etc.] symptoms in women, it's a field that has a large placebo effect," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge. "It needs to have a bigger trial." Prior studies have shown that acupuncture can reduce hot flashes in postmenopausal women without breast cancer. All of these studies, however, compared acupuncture to sham acupuncture, not to commonly used drugs, Walker noted. This is the first randomized controlled study to compare acupuncture alongside medication. Many women with breast cancer receive anti-estrogen hormone therapy, usually for as long as five years, in addition to other treatments. Although hormone therapy is effective in reducing tumor recurrence, it does cause hot flashes and night sweats. The antidepressant Effexor (venlafaxine) is the most commonly used therapy for relieving these symptoms, but the drug brings its own problems, namely dry mouth, reduced appetite, nausea and constipation. "We need something that's accessible that doesn't add adverse effects," Walker said. For this study, 50 women with breast cancer were randomly assigned to receive 12 weeks of acupuncture (twice a week for four weeks then once a week) or daily Effexor. They were followed for a year. Initially, both groups of women experienced similar reductions (about 50 percent) in hot flashes and depression, with an overall improvement in quality of life. But the acupuncture benefits were longer lived. Two weeks out, women taking the antidepressant saw a resurgence in hot flashes while women in the acupuncture arm continued to have far fewer problems. About 25 percent of women receiving acupuncture also reported more interest in sex while many also reported more energy and clearer thinking. "The issue most of the time is the cost of it and whether insurance companies will pay for it," Walker said. Additional studies also need to look at how often women would need booster acupuncture to minimize their symptoms. More information There's more on breast cancer treatments at the U.S. National Cancer Institute. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction.  This posting includes an audio/video/photo media file: Download Now |
| Posted: 29 Dec 2009 04:54 AM PST EMERYVILLE, Calif., Dec. 29 /PRNewswire-FirstCall/ -- Bionovo, Inc. BNVI announced today the publication of results from its study on the anti-tumor mechanism of BN107. The results of the study, published in the International Journal of Cancer, describe the potential molecular mechanisms mediating the selective pro-apoptotic (cell death) effect induced by BN107 on estrogen receptor negative (ER-) breast cancer cells. Despite favorable advances that treatment options have had on survival, oncologists continue to face challenges in providing safe and effective treatment options for ER- breast cancer patients. In this patient population, the PI3K/Akt/mTOR pathway is often abnormally activated which allows cancer cells to grow uncontrollably and evade death. There are two mTOR protein complexes, mTORC1 and mTORC2, both of which are essential for the control of aberrant survival signals. Agents that can inhibit mTORC1 and mTORC2 at the same time might lead to effective suppression of the Akt/mTOR pathway and result in tumor cell death. The study showed that BN107 decreases the levels of proteins present in the mTORC1 and mTORC2 complexes, resulting in their demise specifically in ER- breast cancer cells. The mTOR pathway as a target for cancer therapies has been actively pursued by many pharmaceutical companies. To the Company's knowledge, this is the first report demonstrating effective inhibition of both mTOR complexes concomitantly through a novel mechanism. As explained by Dr. Sylvia Fong, Research Scientist at Bionovo, "The ability of BN107 to induce cancer cell death is selective. We demonstrate that breast cancer cells lacking estrogen receptors are highly sensitive to BN107. Our studies show that disruption of mTOR signaling mediated by both mTORC1 and mTORC2 complexes is most likely responsible for the anti-tumor effect of BN107. Simply put, BN107 has a unique way to target a specific sub-group of breast cancer cells that currently has no selective treatment. This is exciting." "It is critical to develop novel and safe strategies to effectively treat the patients with ER- breast cancers. We believe BN107 will result in better selectivity to hormone independent tumors based on its unique selectivity and mechanisms of action. Currently the only available treatment for this group, constituting 40% of women diagnosed with breast cancer, is chemotherapy. BN107, an oral drug candidate, should provide a chronic treatment option with a low toxicity profile," said Dr. Isaac Cohen, Chairman and CEO of Bionovo. Bionovo, Inc. Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com. Forward Looking Statements This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise. SOURCE Bionovo, Inc. Copyright 2009 PR Newswire Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| EARLY Act Included in Senate Health Reform Legislation - PR-USA.net Posted: 30 Dec 2009 08:06 AM PST With more young women being diagnosed with breast cancer, the Tigerlily Foundation remains proud to be a key supporter of the Breast Cancer Education and Awareness Requires Learning Young (EARLY) Act. This week, the bill had an important milestone, as it was included in the Senate Health Reform Legislation. Congresswoman Wasserman Schultz praised Senate Majority Leader Harry Reid for inclusion of breast cancer provisions in sweeping health insurance reform legislation that saves lives, saves money, and saves Medicare. The EARLY Act was included in the Manager's Amendment to the Patient Protection and Affordable Care Act which passed the Senate early Monday morning. "I am delighted that the EARLY Act has been included as part of the Senate's health reform bill, and that we are a giant step closer to ensuring that all young women have the tools and resources they need to practice good breast health and detect breast cancer early," said Rep. Wasserman Schultz (FL-20). Congresswoman Wasserman Schultz personally met with Senator Harry Reid about including SB 994, the Senate version of the EARLY Act sponsored by Senator Amy Klobuchar (D-MN), in the manager's amendment of the health reform legislation. Sen. Reid shared her concerns about young women's lack of knowledge and awareness about their breast health, and made it clear that he would do everything he could to include these important provisions in the Senate health care reform bill. "Sen. Klobuchar has championed this legislation and worked hard to get it included in the Senate bill," said Rep. Wasserman Schultz. "Young women throughout America will benefit from her hard work and advocacy." "It gives me great pride that Senator Reid included the EARLY Act in the Senate's Patient Protection and Affordable Care Act," said Rep. Wasserman Schultz. "This once again demonstrates Congress's steadfast commitment to protecting the health of our nation's women. I look forward to continuing to work with Senators Reid, Klobuchar, and all of my colleagues as this critical health care legislation moves through the conference process." The EARLY Act directs the Centers for Disease Control to develop and implement a national education campaign to increase awareness of breast health, family history, and the threats posed by breast cancer in young women. The legislation has the support of more than 40 advocacy organizations, including the American Cancer Society Cancer Action Network and Susan G. Komen for the Cure Advocacy Alliance. "I know that as a breast cancer survivor, I would not have found my cancer early without knowledge and awareness," said Rep. Wasserman Schultz. "To combat breast cancer we need to ensure that every young woman in America can rely upon education and awareness, not simply luck." "Tigerlily Foundation is very proud of the work Rep. Wasserman Schultz, Senator Reid and Senator Klobuchar have done to ensure this important legislation is passed. As a young survivor, like Rep. Wasserman Schultz, I would not be alive today were it now for education and awareness. Other young women need to have these same benefits," - Maimah Karmo. About the Tigerlily Foundation According to the National Cancer Institute, more than 250,000 women age 40 and under in the U.S. will be diagnosed with breast cancer during their lives. Breast cancer is the leading cause of cancer death in young women ages 20 to 45, according to the American Cancer Society. In 2009 alone, the American Cancer Society estimates that there will be more than 25,000 new cases of breast cancer in women younger than 45 and approximately eight of these young women will die from the disease each day. Younger women often have more aggressive breast cancers and higher mortality rates. For more information, visit www.tigerlilyfoundation.org. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| You are subscribed to email updates from Add Images to any RSS Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment